



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Gabapentin

April 21, 2016

### **Non-proprietary name**

Gabapentin

### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection of the Adverse reaction section, the following text should be added (underlined parts are revised):

#### Anaphylaxis:

Anaphylaxis (angioedema, dyspnoea, etc.) may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued, and appropriate measures should be adopted.